Could This Seattle Pot Stock SOAR as Legal Weed Market Expands?
Fifteen states plus the District of Columbia now permit the recreational use of cannabis and Congress is on track to decriminalize marijuana possession on the federal level. As a result, the North American cannabis market is expected to TRIPLE in size from $30 billion to $100 billion by the year 2027 – and one Seattle manufacturer is poised to cash in!
Details in Brand-New Special Report!
Kurt H. Kruger, insider at Qualigen Therapeutics
Kurt H. Kruger Insider Alerts

Get notified the next time Kurt H. Kruger buys or sells Qualigen Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Kurt H. Kruger Insider Information

Mr. Kruger has enjoyed a 30-year career in Medical Technology. His deep involvement in the field has ranged from product design and development as a biomedical engineer to raising capital for, and following, publicly traded medical product companies as an equities research analyst. As a marketing manager at Guidant, now a part of Boston Scientific, he developed the launch plans for the first-ever implantable defibrillator. As a securities analyst he showed perspicuity leading Hambrecht & Quist in providing venture funds for, and then taking public, Ventritex, which was later acquired by St. Jude Medical. After Hambrecht & Quist, Kurt worked as an analyst for Montgomery Securities and Bank of America. Across 20 years of research work, Kurt has overseen the IPOs of over 30 medical products companies, including leadership of the Life Sciences banking effort for WR Hambrecht & Co. Mr. Kruger received a Sc.B. degree in Biomedical Engineering from Brown University; a Master’s degree in Bioengineering from the University of Michigan and a business degree (S.M.) from the Sloan School at the Massachusetts Institute of Technology (MIT). He also completed the premedical post-baccalaureate program at Columbia University.

What is Kurt H. Kruger's net worth?

The estimated net worth of Kurt H. Kruger is at least $22,120.00 as of August 19th, 2021. Mr. Kruger owns 14,000 shares of Qualigen Therapeutics stock worth more than $22,120 as of November 30th. This net worth estimate does not reflect any other investments that Mr. Kruger may own. Learn More.

How do I contact Kurt H. Kruger?

The corporate mailing address for Mr. Kruger and other Qualigen Therapeutics executives is 2042 Corte Del Nogal, Carlsbad CA, 92011. Qualigen Therapeutics can also be reached via phone at (310) 203-1000 and via email at [email protected]

Has Kurt H. Kruger been buying or selling shares of Qualigen Therapeutics?

Kurt H. Kruger has not been actively trading shares of Qualigen Therapeutics during the last ninety days. Most recently, on Thursday, August 19th, Kurt H. Kruger bought 8,000 shares of Qualigen Therapeutics stock. The stock was acquired at an average cost of $1.23 per share, with a total value of $9,840.00. Following the completion of the transaction, the director now directly owns 14,000 shares of the company's stock, valued at $17,220.

Who are Qualigen Therapeutics' active insiders?

Qualigen Therapeutics' insider roster includes Amy Broidrick (EVP), Kurt Kruger (Director), and Michael Poirier (CEO).

Are insiders buying or selling shares of Qualigen Therapeutics?

During the last year, Qualigen Therapeutics insiders bought shares 5 times. They purchased a total of 30,205 shares worth more than $55,566.00. The most recent insider tranaction occured on August, 19th when Director Kurt H. Kruger bought 8,000 shares worth more than $9,840.00. Insiders at Qualigen Therapeutics own 4.7 % of the company.

Information on this page was last updated on 8/19/2021.

Kurt H. Kruger Insider Trading History at Qualigen Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/19/2021Buy8,000$1.23$9,840.0014,000View SEC Filing Icon  
See Full Table

Kurt H. Kruger Buying and Selling Activity at Qualigen Therapeutics

This chart shows Kurt H. Kruger's buying and selling at Qualigen Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Qualigen Therapeutics Company Overview

Qualigen Therapeutics logo
Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARS™. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Los Angeles, CA.
Read More

Today's Range

Now: $1.58
Low: $1.55
High: $2.97

50 Day Range

MA: $1.31
Low: $0.94
High: $2.56

2 Week Range

Now: $1.58
Low: $0.93
High: $4.66


81,985,284 shs

Average Volume

2,472,137 shs

Market Capitalization

$46.00 million

P/E Ratio


Dividend Yield



Economic and National Security Threats Create Lithium Bonanza
The U.S. and China are fighting for new sources of lithium – the linchpin of clean energy. Lithium mining operations have been declared a national emergency. Biden has ordered America's lithium supply chain to be strengthened and investors in lithium exploration companies are rejoicing. We may be entering a decades-long lithium bull run. You don't want to miss it.
Click here for the full story.